WO2003016480A3 - Tgf-$g(a) polypeptides, functional fragments and methods of use therefor - Google Patents

Tgf-$g(a) polypeptides, functional fragments and methods of use therefor Download PDF

Info

Publication number
WO2003016480A3
WO2003016480A3 PCT/US2002/026023 US0226023W WO03016480A3 WO 2003016480 A3 WO2003016480 A3 WO 2003016480A3 US 0226023 W US0226023 W US 0226023W WO 03016480 A3 WO03016480 A3 WO 03016480A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tgf
polypeptides
functional fragments
use therefor
Prior art date
Application number
PCT/US2002/026023
Other languages
French (fr)
Other versions
WO2003016480A2 (en
Inventor
Daniel R Twardzik
Andre Pernet
Thomas S Felker
Stefan Paskell
Original Assignee
Stem Cell Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Pharmaceuticals Inc filed Critical Stem Cell Pharmaceuticals Inc
Priority to AU2002336355A priority Critical patent/AU2002336355A1/en
Publication of WO2003016480A2 publication Critical patent/WO2003016480A2/en
Publication of WO2003016480A3 publication Critical patent/WO2003016480A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Disclosed are TGF-α polypetides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex-vivo and in vivo applications.
PCT/US2002/026023 2001-08-17 2002-08-16 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor WO2003016480A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002336355A AU2002336355A1 (en) 2001-08-17 2002-08-16 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/932,172 2001-08-17
US09/932,172 US6815418B2 (en) 1999-08-19 2001-08-17 TGF-α polypeptides, functional fragments and methods of use therefor

Publications (2)

Publication Number Publication Date
WO2003016480A2 WO2003016480A2 (en) 2003-02-27
WO2003016480A3 true WO2003016480A3 (en) 2004-11-11

Family

ID=25461892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026023 WO2003016480A2 (en) 2001-08-17 2002-08-16 Tgf-$g(a) polypeptides, functional fragments and methods of use therefor

Country Status (3)

Country Link
US (1) US6815418B2 (en)
AU (1) AU2002336355A1 (en)
WO (1) WO2003016480A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273534A (en) * 1997-08-04 2000-11-15 加利福尼亚大学董事会 Method for treating neurological deficits
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
EP1210102B1 (en) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptides, functional fragments and methods of use therefor
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20060184251A1 (en) * 2005-01-07 2006-08-17 Zongtao Zhang Coated medical devices and methods of making and using
JP5058822B2 (en) 2005-01-25 2012-10-24 ファイブ プライム セラピューティクス, インコーポレイテッド Compositions and methods for treating cardiac conditions
CA2609728A1 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CN101588826A (en) * 2006-08-02 2009-11-25 英孚拉玛特公司 Lumen-supporting devices and methods of making and using
WO2008016712A2 (en) * 2006-08-02 2008-02-07 Inframat Corporation Medical devices and methods of making and using
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382562D1 (en) 1982-09-24 1992-06-25 Us Health ANIMAL TISSUE RECOVERY.
US4863899A (en) 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
EP0154434B1 (en) 1984-02-17 1993-01-27 Genentech, Inc. Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
US4749683A (en) 1985-01-25 1988-06-07 President And Fellows Of Harvard College Inhibition of gastric acid secretion with alpha-transforming growth factor
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4874746A (en) 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5102870A (en) 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
US5886141A (en) 1990-10-26 1999-03-23 Takeda Chemical Industries, Ltd. Smooth muscle mitogen peptides and DNA coding therefor
US5229493A (en) 1990-10-26 1993-07-20 Children's Medical Center Corporation Smooth muscle mitogen
JPH04352800A (en) 1990-10-26 1992-12-07 Childrens Medical Center Corp:The Smooth muscle mitogen
US5604202A (en) 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
KR960700067A (en) 1993-01-29 1996-01-19 사우엘 웨이스 GENETIC MODIFICATION OF NEURAL STEM CELLS
DE69626034T2 (en) 1995-11-09 2003-08-14 Takeda Chemical Industries Ltd COMPOSITION FOR IMPROVING PANCREAS FUNCTION
US5814308A (en) 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
CA2266659A1 (en) 1996-11-15 1998-05-28 Paule Poulin Pretreatment with growth factors to protect against cns damage
US6114307A (en) 1996-12-16 2000-09-05 Zymogenetics, Inc. Methods for stimulating pancreatic islet cell regeneration
CN1273534A (en) 1997-08-04 2000-11-15 加利福尼亚大学董事会 Method for treating neurological deficits
EP1175487A2 (en) 1999-02-10 2002-01-30 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand

Also Published As

Publication number Publication date
US6815418B2 (en) 2004-11-09
AU2002336355A1 (en) 2003-03-03
US20020169119A1 (en) 2002-11-14
WO2003016480A2 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
WO2003016480A3 (en) Tgf-$g(a) polypeptides, functional fragments and methods of use therefor
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
WO2004012759A3 (en) Use of erythropoietin
WO2001001748A3 (en) Peptide compounds that bind her2
HK1076113A1 (en) Specific binding agents of human angiopoietin-2
EP1764370A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
WO2001083729A3 (en) Vectors for ocular transduction and use thereof for genetic therapy
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
WO1998049300A3 (en) Truncated vegf-related proteins
EP2301563A3 (en) HSP20 peptides
WO2002078614A3 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
WO2002097030A3 (en) Peptides derived from neural thread proteins and their medical use
WO2003014151A3 (en) Human secreted proteins, their encoding polynucleotides, and uses thereof
WO2004031367A3 (en) Uses of human zven proteins and polynucleotides
WO2003040296A3 (en) Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2003031572A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001012127A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
WO2003046180A3 (en) Human cdnas and proteins and uses thereof
WO2004083381A3 (en) Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
WO2003039484A3 (en) Novel compositions and methods for cancer
EP2075346A3 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
UA84831C2 (en) Coagulation factor vii derivatives
WO2002058724A8 (en) Use of lp82 to treat body weight disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

Kind code of ref document: A2

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP